Diasorin SpAMIL:DIA +3.13%67 EBITDA Margin % is 54.00% as of Dec. 2025, which is 43% above its 10-year median of 37.84. GuruFocus rates MIL:DIA with a GF Score™ of 67/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 87.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Diasorin SpA's EBITDA for the
three
months ended in Dec. 2025 was €159 Mil. Diasorin SpA's Revenue for the
three
months ended in Dec. 2025 was €295 Mil. Therefore, Diasorin SpA's EBITDA margin for the quarter that ended in Dec. 2025 was 54.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Diasorin SpA EBITDA Margin % Related Terms
Diasorin SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:DIA vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (MIL:DIA) has a EBITDA Margin % of 54.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diasorin SpA and its competitors. This is 43% above median its historical median of 37.84. Over the past decade, Diasorin SpA's EBITDA Margin % has ranged from 29.40 to 43.77. According to the industry distribution chart, Diasorin SpA ranks #25 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 12.3%.
Is Diasorin SpA's EBITDA Margin % too high?
Diasorin SpA's current EBITDA Margin % of 54.00% is 43% above median its 10-year median of 37.84. Over the past 10 years, this metric has ranged from a low of 29.40 to a high of 43.77. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Diasorin SpA's value of 54.00% is 938.5% above this industry median. Based on the distribution chart, Diasorin SpA ranks #25 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #25 out of 204 companies for EBITDA Margin %. This places Diasorin SpA in the top 12% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Diasorin SpA's value of 54.00% is 938.5% above this benchmark. Historically, Diasorin SpA's own EBITDA Margin % has ranged from 29.40 to 43.77 over the past decade. While the company's 10-year median is 37.84 vs. the industry median of 5.20, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current EBITDA Margin % of 54.00% is 938.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EBITDA Margin % is 54.00%, which is 43% above median its own 10-year median of 37.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current EBITDA Margin % is 54.00%, which is 43% above median its 10-year median of 37.84 and 938.5% above the Medical Diagnostics & Research industry median of 5.20. Diasorin SpA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current EBITDA Margin % is 54.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
EBITDA Margin %: 54.00% (43% above median its 10-year median of 37.84)
GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
Industry Position: 938.5% above the Medical Diagnostics & Research median (#25 of 204)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
67GF Score
Get the complete analysis for MIL:DIA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
